Get Involved

Acute and Chronic effects of Transcranial Direct Current stimulation in Lewy body dementia patients

Contact phone number: 0191 223 2740 (24 hour answer phone)

Contact email: Dendron@ntw.nhs.uk

People who have Lewy body dementia, either Parkinson’s disease dementia or dementia with Lewy bodies, can have hallucinations. These hallucinations are often visual and may be disturbing for patients. The AC-DC study is the first treatment study aimed at reducing hallucinations.

The patients who can join the AC-DC study are people with Parkinson’s disease dementia or dementia with Lewy bodies, who hallucinate. The treatment is transcranial direct current stimulation.  This is a safe treatment.  It can alter the level of activity in the brain. The use of transcranial direct current stimulation in this study is to reduce activity in the ‘visual’ part of the brain and so lessen the chances of hallucinating.

First, all participants complete some memory and thinking tests either in their own home or at the Clinical Ageing Research Unit (CARU) on the Campus for Ageing and Vitality (old Newcastle General Hospital). Treatment and assessments are carried out over 5 days (Monday to Friday). Treatments will be delivered in CARU on days 1 and 5, but on days 2, 3 and 4, treatment can be in the participant’s own home. The memory and thinking tests will be repeated on day 5. To make the research study a fair trial of the treatment, some participants will receive a placebo treatment and some will have active treatment. Which group you are in is decided at random. We will follow up participants one month and three months after treatment, to see if there are continuing treatment benefits.

First, all participants complete some memory and thinking tests either in their own home or at the Clinical Ageing Research Unit (CARU) on the Campus for Ageing and Vitality (old Newcastle General Hospital). Treatment and assessments are carried out over 5 days (Monday to Friday). Treatments will be delivered in CARU on days 1 and 5, but on days 2, 3 and 4, treatment can be in the participant’s own home. The memory and thinking tests will be repeated on day 5. To make the research study a fair trial of the treatment, some participants will receive a placebo treatment and some will have active treatment. Which group you are in is decided at random. We will follow up participants one month and three months after treatment, to see if there are continuing treatment benefits.

The treatment given in the AC-DC study could provide quick relief from hallucinations if the treatment is effective. This is a pilot study to see if transcranial direct current stimulation can be developed further as a treatment for hallucinations. A bigger study will be carried out if this pilot study shows the treatment is beneficial to patients.

Recruitment to ACDC ends 31st March 2017 and a summary of the study findings should be available by early 2018. Participants in the study will receive a newsletter to tell them how successful the study has been. The results of the analysis of the study will be presented at national and international meetings, and published in academic journals.

Clinical Trials in Dementias and Neurodegeneration (DeNDRoN)

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

ACDC

People who have Lewy body dementia, either Parkinson’s disease dementia or dementia with Lewy bodies, can have hallucinations. These hallucinations are often visual and may be disturbing for patients. The AC-DC study is the first treatment study aimed at reducing hallucinations.

Brains for Dementia Research

Brains for Dementia Research makes it easy for people to help research by donating brain tissue after death. Research using brain tissue from people who did not have dementia is important too.

AD Genetics in Early Onset Alzheimer’s Disease

The AD Genetics – Early Onset Alzheimer’s Disease research study is for people with a diagnosis of Alzheimer’s disease before the age of 65. Participants will be visited at a time and place convenient for them, usually in their own homes. The blood samples, interviews and memory tests take less than 2 hours. The participant’s partner, carer or family member will be interviewed at the same time.

SHAPED

Study of HAllucinations in Parkinson’s disease, Eye disease and Dementia

SUPErB

123I-MIBG Scintigraphy Utility as a biomarker for Prodromal Dementia with Lewy Bodies (SUPErB)

GAITDEM 20642

A study to assess the memory and walking of people

Investigating skin metabolites as a new way to diagnose Parkinson’s disease

This is a research study to investigate the chemicals known as metabolites found on the skin of people with Parkinson’s disease (PD).

Parkinson’s pen project (PPP): Developing a novel non-invasive aid for early diagnosis of Parkinson’s disease

Researchers at a number of universities across Europe (including Newcastle University) have developed a pen system (the Manus platform), which may help doctors to decide whether someone has Parkinson’s disease. Find out more here.


Latest news from PPI

View all